The Scientific Committee invites authors to submit their abstracts for consideration and inclusion in the programme. 

Please click here to submit your abstracts.

Abstract submission deadline: Closed Abstract evaluation deadline: 21 April 2012 Invited speakers abstract submission (no review): from 21 April 2012 until 21 May 2012 Note: all the invited speakers are asked to submit their abstract by clicking on the left horizontal menu "Invited Speakers".

Important:	Please note that only ELECTRONIC submission will be accepted.
	Faxed or mailed abstracts will not be reviewed.

PREPARATION OF YOUR ABSTRACT

• Abstracts must be submitted in English.
  
  
• A “blind” selection process will be used. No identifying features such as names of hospitals, medical schools, clinics or cities may be listed in the title or text of the abstract. Do not include the names of authors either. Their names and affiliations (institutions) will be registered separately when submitting an abstract online.
• The material in the abstract must be original and not previously published.
  
  
• The title should be as brief as possible but long enough to clearly indicate the nature of the study. Abbreviations must not be used in the title.
  
  
• The size of the abstract is limited to 3,000 characters (this includes title, body of abstract, spaces, tables and graphics). The submission programme will automatically calculate the size of your abstract and will not allow submissions that do not fit in the size requirements.  Each section (Introduction & Objectives, Materials & Methods, Results, and Conclusions) should be inserted in the individually labelled boxes.
  
  
• You can click on the relevant icons to insert tables, pictures or specific characters.
  
  
• Structure your abstract using the following subheadings:
  
  • Introduction & Objectives: a sentence describing the purpose of the study
  • Materials & Methods: describe your selection of observations or experimental subjects precisely
  • Results: describe your results in a logical sequence
  • Conclusions: emphasise new and important aspects of the study and conclusions that are drawn from them
          
•        Failure to comply with the following requirements will lead to automatic rejection of the submission:
  
  • Check spelling and grammar carefully. Direct reproduction from your electronically submitted abstract text means that any errors in spelling, grammar or scientific data will be reproduced as submitted.
  • Use generic names. Commercial drug names may not be used. Drugs should be referred to by the active substance or pharmacological designation. 
  • No mention of pharmaceutical company names should be included in the abstract. 

Note: The evaluation and scoring of the abstract (acceptance as poster or as oral communication, or rejection) will be made according to a number of criteria, including:

• Is the content interesting, informative, novel or important?
• Are the methods valid, the results relevant and the conclusions justified by the data?
• Are the data presented with clarity and with appropriate structure?
• Is the text written according to proper English grammar and syntactic style?

The authors have to specify if they wish the submission to presented as:

• Poster presentation only                           
• Oral presentation only
  
• Poster or oral presentation       

              

RULES FOR PRESENTERS AT EADV ACADEMIC MEETINGS

Patient Privacy /Clinical Photographs / Conflict of Interest

PHOTOGRAPHS should at all times protect the privacy and identity of the subject. 

Eyes should be blacked out.
The source of the photographs must also be declared if not the property of the presenter.
This is to prevent the use of photographic material without permission.

Conflict of Interest
A signed Declaration of Interest form is required from all presenters at EADV academic meetings.

It should include:
1. Paid work by commercial organisations either directly or indirectly through an intermediary.
2. Receipt / ownership of shares in commercial companies.
3. Reimbursement of travelling, accommodation and hospitality expenses from commercial organisations.

For further information, please contact abstracts@eadvprague2012.org

COPYRIGHT AND PUBLICATION OF ABSTRACTS

• Submission of an abstract implies that it has been approved by all listed authors.
• The Scientific Programming Committee reserves the right to make the final decision concerning the form of presentation. 
• Accepted abstracts will be published on the official abstract CD ROM, which will be distributed at the Congress in the delegate bags. The abstracts may also be published on the EADV website. Submission of an abstract constitutes your consent to publication (e.g.  Symposium/Congress website, programmes, other promotional material, etc...)
• Abstracts will be published as submitted. Errors will not be amended by the organisers.

SUBMISSION TOPICS  

1. Acne and Related Disorders, Hidradenitis suppurativa
2. Adverse Drug Reactions, TEN 
3. Allergology and Immunology
4. Angiology, Haemangiomas, Vascular Malformations, Vasculitis
5. Atopic Dermatitis/Eczema
6. Autoimmune Bullous Diseases
7. Autoimmune Connective Tissue Disorders
8. Biologics, Immunotherapy, Molecularly Targeted Therapy
9. CME-CPD
10. Contact and Occupational Dermatitis
11. Corrective, Aesthetic and Cosmetic Dermatology
12. Cutaneous Oncology
13. Dermatological Practice Management
14. Dermatological Surgery
15. Dermatology and Internal Medicine, incl. Skin Manifestations of Systemic Diseases
16. Dermatopathology
17. Dermoscopy
18. Diagnostic Procedures
19. Economics in Dermatology, Ethics in Dermatology
20. Epidemiology
21. Genetics
22. Gynaecological Dermatovenereology, Gender Dermatovenereology
23. Hair Disorders/Diseases
24. History of Dermatovenereology
25. Infectious Diseases, Parasitic Diseases, Infestations
26. Inherited Skin Diseases
27. Inflammatory Skin Diseases
28. Lasers 
29. Media, Information and Communication Technology (ICT)
30. Nail Disorders/ Diseases 
31. Oral Mucosa and other Skin-Adjacent Mucous Membranes
32. Paediatric Dermatology
33. Pharmacology and Skin-Related Toxicology, Phlebology  
34. Photobiology and Photoallergy
35. Phototherapy, Photodynamic Therapy
36. Pigmentary Diseases 
37. Pregnancy-Related Dermatoses  
38. Pruritus
39. Psoriasis  
40. Psychodermatology
41. Quality of Life
42. Research in Dermatovenereology, Experimental Dermatovenereology
43. Sexually Transmitted Infections, HIV/ AIDS    
44. Systemic Treatment
45. Topical Therapy
46. Tropical Dermatovenereology
47. Urticaria, Angioedema
48. Wounds, Chronic Wounds, Wound Healing, Ulcers  
49. Miscellaneous